JCI Insight (Feb 2022)

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer

  • Colt A. Egelston,
  • Weihua Guo,
  • Jiayi Tan,
  • Christian Avalos,
  • Diana L. Simons,
  • Min Hui Lim,
  • Yinghui J. Huang,
  • Michael S. Nelson,
  • Arnab Chowdhury,
  • Daniel B. Schmolze,
  • John H. Yim,
  • Laura Kruper,
  • Laleh Melstrom,
  • Kim Margolin,
  • Joanne E. Mortimer,
  • Yuan Yuan,
  • James R. Waisman,
  • Peter P. Lee

Journal volume & issue
Vol. 7, no. 3

Abstract

Read online

CD8+ tumor-infiltrating lymphocytes (TILs) are associated with improved survival in triple-negative breast cancer (TNBC) yet have no association with survival in estrogen receptor–positive (ER+) BC. The basis for these contrasting findings remains elusive. We identified subsets of BC tumors infiltrated by CD8+ T cells with characteristic features of exhausted T cells (TEX). Tumors with abundant CD8+ TEX exhibited a distinct tumor microenvironment marked by amplified interferon-γ signaling–related pathways and higher programmed death ligand 1 expression. Paradoxically, higher levels of tumor-infiltrating CD8+ TEX associated with decreased overall survival of patients with ER+ BC but not patients with TNBC. Moreover, high tumor expression of a CD8+ TEX signature identified dramatically reduced survival in premenopausal, but not postmenopausal, patients with ER+ BC. Finally, we demonstrated the value of a tumor TEX signature score in identifying high-risk premenopausal ER+ BC patients among those with intermediate Oncotype DX Breast Recurrence Scores. Our data highlight the complex relationship between CD8+ TILs, interferon-γ signaling, and ER status in BC patient survival. This work identifies tumor-infiltrating CD8+ TEX as a key feature of reduced survival outcomes in premenopausal patients with early-stage ER+ BC.

Keywords